Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Growth disorders
- Focus Therapeutic Use
- Acronyms EPASOS
- 26 Sep 2017 Planned End Date changed from 1 Dec 2021 to 1 Feb 2016.
- 22 Feb 2016 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.
- 08 Oct 2015 New trial record